CLAUDIUS DAWSON: Open Payments
NPI 1780675306 · SUMMERVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 42 payments from 11 companies in 2025. Trend: 2023 $1,792 · 2024 $918 · 2025 $798
Food & beverage: $798
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $183 |
| Novo Nordisk Inc | 7 | $123 |
| Sumitomo Pharma America, Inc. | 4 | $98 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| Corcept Therapeutics | 4 | $81 |
| Lilly USA, LLC | 4 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Amgen Inc. | 2 | $38 |
| SHIELD THERAPEUTICS INC | 2 | $34 |
| Dexcom, Inc. | 1 | $28 |
Products named: GEMTESA, LEQVIO, Korlym, QULIPTA, VRAYLAR, Rybelsus, CAPLYTA, UBRELVY.
Industry payments across SC — which companies pay providers there.
